TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10730559

Group type: EXPERIMENTAL
Intervention: Mesalazine foam (Salofalk foam) 2 g twice a day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Mesalazine enema (2 g/60 ml twice a day)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Switch to mesalazine foam after initial treatment with enema
Number of subjects: 195

Group type: COMPARATOR
Intervention: Switch to mesalazine enema after initial treatment with foam
Number of subjects: 195
Study: 7793583

Group type: EXPERIMENTAL
Intervention: Propofol emulsion containing 0.05% lignocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol emulsion containing lignocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dosages of lignocaine above 0.05%
Number of subjects: 0
Study: 1827568

Group type: EXPERIMENTAL
Intervention: E/CPA (1 mg cyproterone acetate)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: E/LNG (75 micrograms levonorgestrel)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: E/MPA (10 mg medroxyprogesterone acetate)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: E/DG (150 micrograms desogestrel)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 6165750

Group type: EXPERIMENTAL
Intervention: Chamber A (1000 PNU/ml ragweed extract)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chamber B (buffered saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chamber C (1000 PNU/ml ragweed and 50 ng histamine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chamber D (50 ng histamine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Addition of exogenous histamine (50 ng/ml) to ragweed before injection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ragweed alone (no histamine)
Number of subjects: 8
Study: 30177585

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin followed by maintenance pemetrexed (PC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pemetrexed monotherapy (P)
Number of subjects: 96
Study: 29162123

Group type: EXPERIMENTAL
Intervention: Dark blood late gadolinium enhancement (DB LGE)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Bright blood late gadolinium enhancement (bright blood LGE)
Number of subjects: 172
Study: 26742388

Group type: COMPARATOR
Intervention: Liquid medication
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Non-restricted medication
Number of subjects: 26
Study: 23287846

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (TRF) supplementation (150 mg/day) for 6 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 8
Study: 21687919

Group type: EXPERIMENTAL
Intervention: Alert calls
Number of subjects: 79
Study: 18430685

Group type: EXPERIMENTAL
Intervention: Targeted implanted cortical electrical stimulation of the motor cortex with upper limb rehabilitation therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rehabilitation therapy alone
Number of subjects: 24
Study: 17201251

Group type: EXPERIMENTAL
Intervention: Aildenafil citrate 30 or 60 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 12562652

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ciprofloxacin and roxithromycin)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 11290639

Group type: EXPERIMENTAL
Intervention: Computer intervention combining information from patient's medical record with general information about schizophrenia
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Sessions with a community psychiatric nurse
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combination intervention (first and last sessions with nurse and remainder with computer)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nurse based education
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Computer sessions
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cost analysis of interventions
Number of subjects: 112
Study: 9412807

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 8214921

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3683061

Group type: EXPERIMENTAL
Intervention: CO2 laser surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional surgery (knife/electric knife)
Number of subjects: 60
Study: 30304457

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg daily
Number of subjects: 1034

Group type: COMPARATOR
Intervention: 8% micronized vaginal progesterone (MVP) gel 90 mg daily
Number of subjects: 1034
Study: 28265691

Group type: EXPERIMENTAL
Intervention: BMS-986142 (5-900 mg single dose; 25-350 mg multiple doses, once daily for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-986142 (350 mg, once daily for 5 days)
Number of subjects: 0
Study: 26666916

Group type: EXPERIMENTAL
Intervention: Pyramax (pyronaridine-artesunate combination)
Number of subjects: 349
Study: 23531424

Group type: EXPERIMENTAL
Intervention: Low-residue diet
Number of subjects: 230

Group type: COMPARATOR
Intervention: Clear liquid diet
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 230
Study: 21038171

Group type: EXPERIMENTAL
Intervention: PT + CBT (n = 76)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: PT (n = 71)
Number of subjects: 147

Group type: COMPARATOR
Intervention: UCC (n = 62)
Number of subjects: 147
Study: 18514651

Group type: EXPERIMENTAL
Intervention: D(50)+E
Number of subjects: 92

Group type: COMPARATOR
Intervention: NS+E
Number of subjects: 92
Study: 16308253

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 microg/day) for 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 35
Study: 12827312

Group type: EXPERIMENTAL
Intervention: 2-h elution (group A)
Number of subjects: 161

Group type: COMPARATOR
Intervention: 24-h elution (group B)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 2-h elution (subgroup 1)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 24-h elution (subgroup 3)
Number of subjects: 161
Study: 10962855

Group type: EXPERIMENTAL
Intervention: 100 U calcitonin thrice a week for 3 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 50 U calcitonin thrice a week for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8819498

Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance (8 mg/day with p.o. placebo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methadone maintenance (80 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 12
Study: 1394960

Group type: EXPERIMENTAL
Intervention: Tonifying Manipulation (TM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing Manipulation (RM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 3864038

Group type: EXPERIMENTAL
Intervention: Hyperimmune hepatitis B immunoglobulin (HBIg) administered at birth and six weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mothers who were HBsAg positive but hepatitis Be antigen negative
Number of subjects: 100
Study: 29982413

Group type: EXPERIMENTAL
Intervention: Remote Activity Monitoring (RAM)
Number of subjects: 132
Study: 29037773

Group type: EXPERIMENTAL
Intervention: S+NAC500 (simethicone 200 mg + N-acetylcysteine 500 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: S+NAC1000 (simethicone 200 mg + N-acetylcysteine 1000 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: S (simethicone 200 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Water (100 mL)
Number of subjects: 230
Study: 26952680

Group type: EXPERIMENTAL
Intervention: Finding Balance Intervention (FBI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (received FBI at a second visit)
Number of subjects: 19
Study: 24013857

Group type: EXPERIMENTAL
Intervention: Free-breathing phase contrast (PC) imaging
Number of subjects: 6

Group type: COMPARATOR
Intervention: Breath-hold phase contrast (PC) imaging
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tissue Doppler imaging (TDI)
Number of subjects: 6
Study: 22642853

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 140
Study: 20205485

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study: 18568571

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 16024862

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenously before and after surgery, continued orally for 4 days at 20 mg/kg/8 hours)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 62
Study: 12180109

Group type: EXPERIMENTAL
Intervention: 15-day catheter dressing change frequency
Number of subjects: 112

Group type: COMPARATOR
Intervention: 4-day catheter dressing change frequency
Number of subjects: 112
Study: 10335412

Group type: EXPERIMENTAL
Intervention: Homeopathic remedies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7492197

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 micrograms/puff, two puffs twice daily for eight weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (two puffs twice daily for eight weeks)
Number of subjects: 50
Study: 8185085

Group type: EXPERIMENTAL
Intervention: AES followed by saline (AS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AES followed by naloxone (AN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo AES followed by saline (PS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo AES followed by naloxone (PN)
Number of subjects: 40
Study: 3940829

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 24
Study: 30160313

Group type: EXPERIMENTAL
Intervention: CABG with BMMNC graft
Number of subjects: 42

Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 42
Study: 26363250

Group type: EXPERIMENTAL
Intervention: Lumbar fusion
Number of subjects: 294

Group type: COMPARATOR
Intervention: Non-specific physiotherapy (control)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Lumbar fusion and Non-specific physiotherapy
Number of subjects: 294
Study: 24231197

Group type: EXPERIMENTAL
Intervention: Double-lumen tube (DLT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bronchial blocker (BB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bronchial blocker with disconnection technique (BB with disconnection)
Number of subjects: 52
Study: 21975468

Group type: EXPERIMENTAL
Intervention: Walking exercise programme (increased to 3000 steps more than before)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 20683173

Group type: EXPERIMENTAL
Intervention: Orlistat plus L-carnitine (orlistat 120 mg three times a day plus L-carnitine 2 g one time a day)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Orlistat (orlistat 120 mg three times a day)
Number of subjects: 258
Study: 18762633

Group type: EXPERIMENTAL
Intervention: 4 percent articaine with 1:100,000 epinephrine
Number of subjects: 73

Group type: COMPARATOR
Intervention: 2 percent lidocaine with 1:100,000 epinephrine
Number of subjects: 73
Study: 16122669

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 12594639

Group type: EXPERIMENTAL
Intervention: Nonchlamydial antigen immunization (yellow fever, polio, diphtheria, and tetanus)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline injections (placebo)
Number of subjects: 48
Study: 9803652

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopy
Number of subjects: 882
Study: 7986714

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with blood progenitor transplantation (priming regimen: cyclophosphamide 3 g/m2, etoposide 900 mg/m2 with GM-CSF; high-dose chemotherapy: thiotepa 750 mg/m2, busulfan 10 mg/kg, cyclophosphamide 120 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control patients who did not receive intensive treatment
Number of subjects: 17
Study: 3236383

Group type: EXPERIMENTAL
Intervention: Written behavioral prescriptions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Verbal behavioral prescriptions
Number of subjects: 30
Study: 5090761

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg twice daily)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Slow-K (32 mEq daily)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Triamterene (50 mg twice daily)
Number of subjects: 3
Study: 31365801

Group type: EXPERIMENTAL
Intervention: ibrutinib-rituximab
Number of subjects: 529

Group type: COMPARATOR
Intervention: chemoimmunotherapy
Number of subjects: 529
Study: 28918642

Group type: EXPERIMENTAL
Intervention: Oral healthcare program administered for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 26687696

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg SC every 2 weeks (Q2W)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/d
Number of subjects: 361

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/d (rechallenge)
Number of subjects: 361
Study: 24490169

Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration
Number of subjects: 51

Group type: COMPARATOR
Intervention: Merci/Penumbra systems
Number of subjects: 51
Study: 21636808

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1 g of vitamin C
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18088263

Group type: EXPERIMENTAL
Intervention: Community nurse visits before discharge, within seven days of discharge, weekly for four weeks, then monthly.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard follow-up in specialist medical clinics)
Number of subjects: 105
Study: 16423737

Group type: EXPERIMENTAL
Intervention: Exposure to psychological stressor
Number of subjects: 0
Study: 12603639

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 2113

Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 2113

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2113
Study: 10860187

Group type: EXPERIMENTAL
Intervention: Multiple insulin injection therapy (MIT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional insulin injection therapy (CIT)
Number of subjects: 110
Study: 9263111

Group type: EXPERIMENTAL
Intervention: Amicus double-needle plateletapheresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amicus single-needle procedures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amicus
Number of subjects: 30
Study: 7684080

Group type: EXPERIMENTAL
Intervention: Seven pediculicidal agents with their supplied nit removal combs
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 223
Study: 2949059

Group type: EXPERIMENTAL
Intervention: SKF 38393 (selective D‐1 dopamine receptor agonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SKF 38393 combined with intravenous levodopa
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30261898

Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Crystalloids
Number of subjects: 1741
Study: 27687435

Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lightwand
Number of subjects: 60
Study: 25614126

Group type: EXPERIMENTAL
Intervention: Plant stanols (2 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Plant sterols (2 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sitostanol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sitosterol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (margarine without plant stanols/sterols)
Number of subjects: 36
Study: 23549137

Group type: EXPERIMENTAL
Intervention: Tonic containing urea, lactate, polidocanol, and Glycyrrhiza inflata root extract applied three times a week for 4 weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tonic containing urea and lactate.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tonic treatment.
Number of subjects: 30
Study: 20956842

Group type: EXPERIMENTAL
Intervention: Functional Circuit Training (FCT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 51
Study: 19125830

Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin (SimMan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fidelity mannequin (Laerdal Heart Start 2000)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subjective outcomes
Number of subjects: 12
Study: 17277653

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (LPLC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum
Number of subjects: 40
Study: 12689847

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional-weaning approach
Number of subjects: 43
Study: 10389553

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg
Number of subjects: 861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study: 8891185

Group type: EXPERIMENTAL
Intervention: 200 mG intermittent, circularly polarized magnetic fields
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 200 mG field condition
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham exposure (night 1)
Number of subjects: 73
Study: 2004528

Group type: EXPERIMENTAL
Intervention: Eutectic combination of EE:CHOL (50 mg of mixture providing 0.050 mg of ethinylestradiol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 50 micrograms tablet of ethinylestradiol (Dianor, Syntex)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eutectic combination of EE:CHOL
Number of subjects: 6
Study: 7047686

Group type: EXPERIMENTAL
Intervention: Azathioprine therapy (2 mg/kg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (not treated with cytostatics)
Number of subjects: 115
Study: 31543215

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) as a periprocedural bridging anticoagulant
Number of subjects: 9278
Study: 29936918

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1.25 mg vitamin D3 monthly for 24 months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Consistently vitamin D sufficient (25(OH)D>50 nmol/l at both months 3 and 24)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not consistently vitamin D sufficient (25(OH)D≤50 nmol/l at either month 3 or 24)
Number of subjects: 200
Study: 27384676

Group type: EXPERIMENTAL
Intervention: DDGP regimen (cisplatin, dexamethasone, gemcitabine, pegaspargase); 6 cycles of chemotherapy
Number of subjects: 25
Study: 25102730

Group type: EXPERIMENTAL
Intervention: Cytoflavin administration combined with standard therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 0
Study: 21319349

Group type: EXPERIMENTAL
Intervention: Itraconazole prophylaxis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Empirical treatment
Number of subjects: 55
Study: 19390459

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Combination therapy (Olmesartan + Pravastatin)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 190
Study: 16427787

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12632691

Group type: EXPERIMENTAL
Intervention: Diabetes education program
Number of subjects: 428
Study: 11789242

Group type: EXPERIMENTAL
Intervention: Changmaishu (CMS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Salvia injection and Di'ao Xinxuekang (Control)
Number of subjects: 80
Study: 9375537

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 10% MVC for 65 min (test B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 10% MVC following maximum contraction for 4 min (test A)
Number of subjects: 12
Study: 1549521

Group type: EXPERIMENTAL
Intervention: 7.2 degrees C blanket
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 23.9 degrees C blanket
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Warmer blanket temperatures
Number of subjects: 89

Group type: COMPARATOR
Intervention: All groups (7.2, 12.8, 18.3, 23.9 degrees C)
Number of subjects: 89
Study: 4028810

Group type: EXPERIMENTAL
Intervention: 2 mg lormetazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: 2 mg flunitrazepam
Number of subjects: 6
Study: 30995350

Group type: EXPERIMENTAL
Intervention: Active Re‐timer®
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo Re‐timer® (dimmer with neutral density filters)
Number of subjects: 15
Study: 29025406

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/die
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/die
Number of subjects: 75
Study: 26736984

Group type: EXPERIMENTAL
Intervention: Simvastatin with itraconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 0